GENE ONLINE|News &
Opinion
Blog

2021-07-01| China

China’s Simcere Gains Regional Rights for Two Alzheimer’s Drugs

by Tyler Chen
Share To

The market for Alzheimer’s disease (AD) drugs in China is estimated to reach $2 billion by 2027 with a CAGR of 10.3%, outpacing several big economies such as Japan, Canada, Europe, and Germany. The substantial growth attracts several overseas investments from pharmaceutical companies.

 

A $565 Million Collaboration

On June 29th, China’s Simcere Pharmaceutical announced a licensing deal worth $565 million with Germany’s Vivoryon Therapeutics N.V. to develop and commercialize two of Vivoryon’s investigational AD drugs, specifically in China.

“In partnering with Simcere, who is continuously recognized as one of the top innovative pharmaceutical and manufacturing enterprises in China, we hope to be able to make an impact beyond our own focus of developing PQ912 towards the markets in Europe and the US,” said Michael Schaeffer, Ph.D., Vivoryon’s Chief Business Officer.

 

Regional License for Two Alzheimer’s Drugs

The two drugs are varoglutamstat (PQ912), an oral pill, and PBD-C06, an antibody.

PQ912 is an orally-taken small-molecule inhibitor of glutaminyl cyclase (QPCT) that can target neurotoxic N3pE amyloid, a driver of AD. Currently, it is in the Phase 2b clinical trial in Europe. In addition, Vivoryon plans to conduct a Phase 2a/b trial in the US in the second half of 2021.

On the other hand, PBD-C06 is a humanized and de-immunized IgG1 antibody that removes the N3pE amyloid from the brain. The drug is also designed with low immunogenicity and low potency so that it won’t induce amyloid-related imaging abnormalities (ARIAs), a severe side effect of antibody-based AD therapies. For now, PBD-C06 is in the preclinical stage.

Under the agreement, Simcere will receive licenses to develop and sell both drugs in the China region. Except for the total amount of the deal, many of the financial details remained undisclosed, but Vivoryon will obtain double-digit royalties on sales.

Related Article: Biogen’s Controversial Alzheimer’s Drug Wins Historic FDA Approval

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
R&D
Intermittent Fasting Improves Alzheimer’s Pathology, Possibly Breaks New Ground for Future Research
2023-08-24
R&D
Scientists Have Identified 32 Proteins Associated with Dementia Risk: A Promising Step Towards Early Detection and Potential Treatments
2023-08-02
Sanofi and AstraZeneca’s RSV Antibody Drug Gets FDA Approval, Adding New Weapon for Preventing Infant Infections
2023-07-18
LATEST
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
2023-09-29
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
2023-09-28
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
2023-09-27
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
2023-09-27
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
2023-09-27
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
2023-09-27
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
2023-09-26
EVENT
2023-10-04
BioFuture 2023
New York city,USA
Scroll to Top